Medtronic climbs on $585 million CathWorks acquisition

Medtronic

03/02/2026 17:28

** Shares of medical device maker Medtronic MDT.N rise 1.6% to $104.39

** Co says it will buy privately held CathWorks in a deal worth up to $585 mln to strengthen its heart devices business

** The deal follows a partnership signed in 2022 and is expected to close by the end of Medtronic's fiscal 2026, pending U.S. regulatory approval

** Leerink Partners analysts said the CathWorks deal is "positive for the stock," reflecting Medtronic's renewed focus on growth and strategic investments

** The deal adds CathWorks' FFRangio System, a non‑invasive tool that evaluates coronary artery disease, the most common heart condition caused by plaque buildup that restricts blood flow

** Heart devices, including pacemakers and the fast‑growing pulsed field ablation business, make up nearly 40% of Medtronic's revenue

** MDT gained 19.7% in 2025

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))